Molecular genetics and treatment of narcolepsy

References

• American Academy of Sleep Medicine. International classification of sleep disorders, 2nd edition. Diagnostic and coding manual. American Academy of Sleep Medicine, Westchester, Illinois 2005
   Google Scholar
• Dauvilliers Y., Billiard M., Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114: 2000–17
   PubMed Web of Science ®Google Scholar
• Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50: 16–22
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Maret S., Bassetti C., Carlander C., Billiard M., Touchon J., et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin‐1. Neurology 2004; 62: 2137–8
   PubMed Web of Science ®Google Scholar
• Khatami R., Maret S., Werth E., Retey J., Schmid D., Maly F., et al. Monozygotic twins concordant for narcolepsy‐cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 2004; 363: 1199–200
   PubMedGoogle Scholar
• Lin L., Faraco J., Li R., Kadotani H., Rodgers W., Lin Y., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365–76
   PubMed Web of Science ®Google Scholar
• Chemelli R. M., Willie J. T., Sinton C. M., Elmquist J. K., Scammel T., Lee C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437–51
   PubMed Web of Science ®Google Scholar
• Nishino S., Ripley B., Overeem S., Lammers G. L., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39–40
   PubMed Web of Science ®Google Scholar
• Mignot E., Lammers G. J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnostic of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553–62
   PubMed Web of Science ®Google Scholar
• Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991–7
   PubMed Web of Science ®Google Scholar
• Thannickal T. C., Moore R. Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469–74
   PubMed Web of Science ®Google Scholar
• Lecendreux M., Maret S., Bassetti C., Mouren M. C., Tafti M. Clinical efficacy of high‐dose intravenous immunoglobulins near the onset of narcolepsy in a 10‐year‐old boy. J Sleep Res 2003; 12: 347–8
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Carlander B., Rivier F., Touchon J., Tafti M. Successful management of cataplexy with intravenous immunoglobulins shortly after narcolepsy onset. Ann Neurol 2004; 56: 905–08
   PubMed Web of Science ®Google Scholar
• Mignot E., Lin L., Rogers W., Honda Y., Qiu X., Lin X., et al. Complex HLA‐DR and DQ interactions confer risk of narcolepsy‐cataplexy in three ethnic groups. Am J Hum Genet 2001; 68: 686–99
   PubMed Web of Science ®Google Scholar
• Honda Y., Asaka A., Tanaka Y., Juji T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res 1983; 12: 254
   Google Scholar
• Billiard M., Seignalet J. Extraordinary association between HLA‐DR2 and narcolepsy. The Lancet 1985; 1: 226–7
   Google Scholar
• Neely S., Rosenberg R., Spire J. P., Antel J., Arnason B. G. HLA antigens in narcolepsy. Neurology 1987; 37: 1858–60
   PubMed Web of Science ®Google Scholar
• Lin L., Hungs M., Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2001; 117: 9–20
   PubMed Web of Science ®Google Scholar
• Pelin Z., Guilleminault C., Risch N., Grumet F. C., Mignot E. HLA‐DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998; 51: 96–100
   PubMedGoogle Scholar
• Sakurai T., Amemiya A., Ishii I., Matzusaki I., Chemelli R. M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G‐protein‐coupled receptors that regulate feeding behavior. Cell 1998; 92: 573–85
   PubMed Web of Science ®Google Scholar
• Hara J. C., Beukmann T., Nambu T., Willie J. T., Chemelli R. M., Sinton C. M., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345–54
   PubMed Web of Science ®Google Scholar
• Gencik M., Dahmen N., Wieczorek S., Kasten M., Bierbrauer J., Anghelescu I., et al. A preproorexin gene polymorphism is associated with narcolepsy. Neurology 2000; 56: 115–7
   Google Scholar
• Hungs M., Lin L., Okun M., Mignot E. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001; 57: 1893–5
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Baumann C. R., Carlander B., Bischof M., Blatter T., Lecendreux M., et al. CSF hypocretin1 levels in Narcolepsy, KleineLevin syndrome and other Hypersomnia and Neurological conditions. J Neurol Neurosurg Psychiatry 2003; 74: 1667–73
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze M., Besset A., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029–33
   PubMed Web of Science ®Google Scholar
• Koch H., Craig I., Dahlitz M., Denney R., Parkes D. Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy. Lancet 1999; 353: 645–6
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Neidhart E., Lecendreux M., Billard M., Tafti M. MAO‐A and COMT polymorphisms and gene effects on narcolepsy. Mol Psychiatry 2001; 6: 367–72
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Neidhart E., Billiard M., Tafti M. Sexual dimorphism of the catechol‐O‐methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2002; 2: 65–8
   PubMedGoogle Scholar
• Wieczorek S., Jagiello P., Arning L., Dahmen N., Epplen J. T. Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA. J Mol Med 2004; 82: 696–705
   PubMedGoogle Scholar
• Fehr C., Schleicher A., Szegedi A., Anghelescu I., Klawe C., Hiemke C., et al. Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 965–82
   PubMedGoogle Scholar
• Hohjoh H., Nakayama T., Ohashi J., Miyagawa T., Tanaka H., Akaza T., et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor alpha gene promoter with human narcolepsy. Tissue Antigens 1999; 54: 138–45
   PubMedGoogle Scholar
• Wieczorek S., Gencik M., Rujescu D., Tonn P., Giegling I., Epplen J. T., et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003; 61: 437–42
   PubMedGoogle Scholar
• Hohjoh H., Terada N., Kawashima M., Honda Y., Tokunaga K. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000; 56: 446–8
   PubMedGoogle Scholar
• Gencik M., Dahmen N., Wieczorek S., Kasten M., Gencikova A., Epplen J. T. ApoE polymorphisms in narcolepsy. BMC Med Genet 2001; 2: 9–10
   PubMedGoogle Scholar
• Billiard M., Pasquié‐Magnetto V., Heckmann M., Carlander B., Besset A., Zachariev Z., et al. Family studies in narcolepsy. Sleep 1994; 17: S54–S59
   PubMed Web of Science ®Google Scholar
• Nakayama J., Miura M., Honda M., Miki T., Honda Y., Arinami T. Linkage of human narcolepsy with HLA association to chromosome 4p13‐q21. Genomics 2000; 65: 84–6
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y., Blouin J. L., Neidhart E., Carlander B., Eliaou J. F., Antonarakis S. E., et al. A Narcolepsy Susceptibility Locus Maps to a 5Mb Region of Chromosome 21q. Ann Neurol 2004; 56: 382–8
   PubMed Web of Science ®Google Scholar
• Dominguez‐Ortega L., Salin‐Pascual R. J., Diaz‐Gallego E. Narcolepsy‐like symptoms in a patient with down syndrome and without obstructive sleep apnea. Sleep 2003; 26: 285–6
   PubMedGoogle Scholar
• Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24: 451–66
   PubMedGoogle Scholar
• Mignot E., Nishino S., Guilleminault C., Dement W. C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436–7
   PubMed Web of Science ®Google Scholar
• Wisor J. P., Eriksson K. S. Dopaminergic‐adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132: 1027–34
   PubMed Web of Science ®Google Scholar
• Ferraro L., Tanganelli S., O'Connor W. T., Antonelli T., Rambert F., Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996; 306: 33–9
   PubMed Web of Science ®Google Scholar
• Lin J. S., Roussel B., Akaoka H., Fort P., de Billy G., Jouvet M. Role of catecholamines in modafinil and amphetamine induced wakefulness, a comparative pharmacological study. Brain Res 1992; 591: 319–26
   PubMed Web of Science ®Google Scholar
• Gallopin T., Luppi P. H., Rambert F. A., Frydman A., Fort P. Effect of the wake‐promoting agent modafinil on sleep‐promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27: 19–25
   PubMed Web of Science ®Google Scholar
• Billiard M., Besset A., Montplaisir J. Modafinil: a double‐blind multicenter study. Sleep 1994; 17: 107–12
   PubMed Web of Science ®Google Scholar
• Broughton R. J., Fleming J. A. E., George C. F. P., Hill J. D., Kryger M. H., Moldofsky H., et al. Randomized, double‐blind, placebo‐controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444–51
   PubMed Web of Science ®Google Scholar
• U.S. Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88–97
   PubMedGoogle Scholar
• U.S. Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166–75
   PubMedGoogle Scholar
• Houghton W. C., Scammell T. E., Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 2004; 8: 355–66
   PubMed Web of Science ®Google Scholar
• Broughton R., Mamelak M. The treatment of narcolepsy‐cataplexy with nocturnal gammahydroxybutyrate. Can J Neurol Sci 1979; 6: 1–6
   PubMed Web of Science ®Google Scholar
• Lammers G. J., Arends J., Declerck A. C., Ferrari M. D., Schouwink G., Troost J. Gammahydroxybutyrate and narcolepsy: a double‐blind placebo‐controlled study. Sleep 1993; 16: 216–20
   PubMed Web of Science ®Google Scholar
• U.S. Xyrem® Multicenter Study group. A randomized, double‐blind, placebo‐controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42–9
   PubMedGoogle Scholar
• U.S. Xyrem® Multicenter Study group. A 12‐month, open‐label multi‐center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26: 31–5
   PubMedGoogle Scholar
• Janota O. Symptomatische Behandlung der pathologischen Schlafsucht, besonders der Narkolepsie. Med Klin 1931; 27: 278–1
   Google Scholar
• Prinzmetal M., Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA 1935; 105: 2051–4
   Google Scholar
• Prinzmetal M., Alles G. A. Central nervous system stimulant effects of dextroamphetamine sulfate. Am J Med Sci 1940; 200: 665–73
   Google Scholar
• Passouant P., Schwab R. S., Cadilhac J., Baldy‐Moulinier M. Narcolepsie‐cataplexie. Étude du sommeil de nuit et du sommeil de jour. Traitement par une amphétamine lévogyre. Rev Neurol 1964; 3: 415–26
   Google Scholar
• Eaton L. M. Treatment of narcolepsy with desoxyephedrine hydrochloride. Proc Staff Meet Mayo Clin 1943; 18: 262–4
   Google Scholar
• Guilleminault C. Amphetamines and narcolepsy: use of the Stanford database. Sleep 1993; 16: 199–201
   PubMedGoogle Scholar
• Mitler M. M., Aldrich M. S., Koob G. F., Zarcone V. Narcolepsy and its treatment with stimulants (ASDA standards of practice). Sleep 1994; 17: 352–71
   PubMed Web of Science ®Google Scholar
• Parkes J. D., Dahlitz M. Amphetamine prescription. Sleep 1993; 16: 201–3
   PubMedGoogle Scholar
• Yoss R. E., Daly D. Treatment of narcolepsy with Ritalin. Neurology 1959; 9: 171–3
   PubMed Web of Science ®Google Scholar
• Mitler M. M., Shafor R., Hajdukovik R., Timms R. M., Browman C. P. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260–4
   PubMed Web of Science ®Google Scholar
• Shindler J., Schachter M., Brincat S., Parkes J. D. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 1985; 290: 1167–70
   PubMed Web of Science ®Google Scholar
• Alvarez B., Dahlitz M., Grimshaw J., Parkes J. D. Mazindol in long‐term treatment of narcolepsy. Lancet 1991; 337: 1293–4
   PubMedGoogle Scholar
• Honda Y., Hishikawa Y. A long‐term treatment of narcolepsy and excessive daytime sleepiness with pemoline (Bentanamin®). Curr Ther Res 1980; 27: 429–41
   Google Scholar
• Hublin C., Partinen M., Heinonen E., Puuka P., Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095–101
   PubMed Web of Science ®Google Scholar
• Mayer G., Meier‐Ewert K. Selegiline hydrochloride treatment in narcolepsy. A double‐blind, placebo‐controlled study. Clin Neuropharmacol 1995; 18: 306–19
   PubMed Web of Science ®Google Scholar
• Wyatt R., Fram D., Buchbinder R., Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 1971; 285: 987–99
   PubMed Web of Science ®Google Scholar
• Scrima L., Hartman P. G., Johnson F. H., Jr., Hiller F. C. Efficacy of gamma‐hydroxybutyrate versus placebo in treating narcolepsy‐cataplexy: double‐blind subjective measures. Biol Psych 1989; 2: 331–43
   Google Scholar
• U.S. Xyrem® Multicenter Study group. Sodium oxybate demonstrates long‐term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004; 5: 119–23
   PubMedGoogle Scholar
• Akimoto H., Honda Y., Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960; 21: 1–3
   Google Scholar
• Passouant P., Baldy‐Moulinier M. Données actuelles sur le traitement de la narcolepsie. Action des imipraminiques. Concours Médical 1970; 92: 1967–70
   Google Scholar
• Hishikawa Y., Ida H., Nakai K., Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci 1965; 3: 453–61
   Google Scholar
• Schmidt H. S., Clark R. W., Hyman P. R. Protriptyline: an effective agent in the treatment of the narcolepsy‐cataplexy syndrome and hypersomnia. Am J Psychiatry 1977; 134: 183–5
   PubMed Web of Science ®Google Scholar
• Parkes D., Schachter M. Clomipramine and and clonazepam in narcolepsy. Lancet 1979; 2: 1085–6
   PubMed Web of Science ®Google Scholar
• Langdon N., Bandak S., Shindler J., Parkes J. D. Fluoxetine in the treatment of cataplexy. Sleep 1986; 9: 371–2
   PubMed Web of Science ®Google Scholar
• Schachter M., Parkes J. D. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980; 43: 171–4
   PubMed Web of Science ®Google Scholar
• Thirumalai and Shubin. The use of citalopram in resistant cataplexy. Sleep Med 2000; 1: 313–6
   PubMedGoogle Scholar
• Guilleminault C., Mancuso J., Quera Salva M. A., Hayes B., Milter M., Poirier G., et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1986; 9: 275–9
   PubMed Web of Science ®Google Scholar
• Larrosa O., de la Liave Y., Barrio S., Granizo J. J., Garcia‐Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy. Sleep 2001; 24: 282–5
   PubMed Web of Science ®Google Scholar
• Smith M., Parkes J. D., Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996; 5: 217
   Google Scholar
• Vespignani H., Barroche G., Escaillas, Weber M. Importance of mazindol in the treatment of narcolepsy. Sleep 1984; 7: 274–5
   PubMedGoogle Scholar
• Iijima S., Sugita Y., Teshima Y., Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986; 9: 265–8
   PubMed Web of Science ®Google Scholar
• Montplaisir J., Michaud M., Denesle R., Gosselin A. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med 2000; 1: 163–7
   PubMed Web of Science ®Google Scholar
• Roth B., Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweiz Arch Neurol Psychiatry 1975; 116: 291–300
   Google Scholar